{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:04:44Z","timestamp":1789632284413,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:00:00Z","timestamp":1719619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017577","name":"CTI Biopharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017577","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clml.2024.06.012","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T18:21:26Z","timestamp":1719944486000},"page":"796-803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0891-1744","authenticated-orcid":false,"given":"Nico","family":"Gagelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-5712","authenticated-orcid":false,"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal P.","family":"McLornan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-6217","authenticated-orcid":false,"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa-Kathrin","family":"Al-Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5684-2017","authenticated-orcid":false,"given":"Philipp","family":"Treskes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karisse","family":"Roman-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.clml.2024.06.012_bib0001","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.2022017423","volume":"141","author":"Passamonti","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.06.012_bib0002","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajh.26020","volume":"96","author":"Polverelli","year":"2021","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.clml.2024.06.012_bib0003","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2024.06.012_bib0004","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.clml.2024.06.012_bib0005","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/14656566.2023.2203318","article-title":"Cytopenic myelofibrosis: prevalence, relevance, and treatment","volume":"24","author":"Vachhani","year":"2023","journal-title":"Expert Opin Pharmacother"},{"issue":"19","key":"10.1016\/j.clml.2024.06.012_bib0006","doi-asserted-by":"crossref","first-page":"5835","DOI":"10.1182\/bloodadvances.2023010151","article-title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","volume":"7","author":"Oh","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2024.06.012_bib0007","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.06.012_bib0008","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2024.06.012_bib0009","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/JEP.S110702","article-title":"Comprehensive kinase profile of pacritinib, a nonmyelosuppressive janus kinase 2 inhibitor","volume":"8","author":"Singer","year":"2016","journal-title":"J Exp Pharmacol"},{"issue":"1","key":"10.1016\/j.clml.2024.06.012_bib0010","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jmpt.2003.11.003","article-title":"Assessing the clinical significance of change scores recorded on subjective outcome measures","volume":"27","author":"Hurst","year":"2004","journal-title":"J Manip Physiol Ther"},{"issue":"2","key":"10.1016\/j.clml.2024.06.012_bib0011","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-022-01767-y","article-title":"Biological drivers of clinical phenotype in myelofibrosis","volume":"37","author":"Mascarenhas","year":"2023","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2024.06.012_bib0012","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/ajh.26935","article-title":"Comprehensive profiling of clinical JAK inhibitors in myeloproliferative neoplasms","volume":"98","author":"Kong","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.06.012_bib0013","doi-asserted-by":"crossref","unstructured":"Pemmaraju N, Harrison C, Gupta V, et al. Risk-adjusted safety analysis of the oral JAK2\/IRAK1 inhibitor pacritinib in patients with myelofibrosis. eJHaem. 2022;3(4):1346-1351. doi:10.1002\/jha2.591.","DOI":"10.1002\/jha2.591"},{"issue":"13","key":"10.1016\/j.clml.2024.06.012_bib0014","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1002\/cncr.34205","article-title":"Defining disease modification in myelofibrosis in the era of targeted therapy","volume":"128","author":"Pemmaraju","year":"2022","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.clml.2024.06.012_bib0015","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1200\/JCO.21.02246","article-title":"Disease modification in myelofibrosis: an elusive goal?","volume":"40","author":"Vachhani","year":"2022","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.06.012_bib0016","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41409-023-01968-8","article-title":"Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis","volume":"58","author":"Luther","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"10.1016\/j.clml.2024.06.012_bib0017","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/bmt.2012.249","article-title":"Effects of spleen status on early outcomes after hematopoietic cell transplantation","volume":"48","author":"Akpek","year":"2013","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"10.1016\/j.clml.2024.06.012_bib0018","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S2352-3026(22)00330-1","article-title":"Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a position paper on behalf of the chronic malignancies working party of the EBMT","volume":"10","author":"Polverelli","year":"2023","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.clml.2024.06.012_bib0019","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/bmt.2009.188","article-title":"Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone marrow transplant","volume":"45","author":"Bacigalupo","year":"2010","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"10.1016\/j.clml.2024.06.012_bib0020","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41409-023-01924-6","article-title":"Benchmarking of survival outcomes following haematopoietic stem cell transplantation (HSCT): an update of the ongoing project of the European society for blood and marrow transplantation (EBMT) and joint accreditation committee of ISCT and EBMT (JACIE)","volume":"58","author":"Saccardi","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.06.012_bib0021","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood-2023-178645","article-title":"Updated findings of a phase II study of ruxolitinib pre-, during- and post-hematopoietic stem cell transplantation for patients with primary or secondary myelofibrosis","volume":"142","author":"Hobbs","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.06.012_bib0022","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1182\/blood-2022-156780","article-title":"The use of fedratinib for myelofibrosis as a potential bridge to hematopoietic stem cell transplantation after ruxolitinib failure: real-world assessment of treatment characteristics and spleen, symptom, and hematologic response","volume":"140","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"issue":"S3","key":"10.1016\/j.clml.2024.06.012_bib0023","doi-asserted-by":"crossref","first-page":"e22295e4","DOI":"10.1097\/01.HS9.0000967908.22295.e4","article-title":"S249: selective Jak2\/Irak1\/Acvr1 inhibitor pacritinib before reduced-intensity conditioning allogeneic stem cell transplantation in myelofibrosis: final analysis of the phase II HOVON-134 trial","volume":"7","author":"Van Dijck","year":"2023","journal-title":"HemaSphere"},{"issue":"45","key":"10.1016\/j.clml.2024.06.012_bib0024","doi-asserted-by":"crossref","first-page":"79073","DOI":"10.18632\/oncotarget.18674","article-title":"Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis","volume":"8","author":"Palandri","year":"2017","journal-title":"Oncotarget"},{"issue":"20","key":"10.1016\/j.clml.2024.06.012_bib0025","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1182\/blood-2018-12-890889","article-title":"Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation","volume":"133","author":"Gagelmann","year":"2019","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T11:09:56Z","timestamp":1729595396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2152265024002465"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.06.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}